Inject4Pain is the new Bluepharma project funded by Portugal 2020, entitled "New biomaterials and their application in innovative formulations of controlled-release injectable medications". It has a duration of 24 months and its completion is scheduled for February 2022.
Inject4Pain continues Bluepharma's technological differentiation strategy initiated in 2017 with the development of complex (initially lipid-based) injectables, which are products with a very high added value and for which there is a huge demand in the market, given the scarcity of pharmaceutical companies with the technical and scientific capacity and skills to develop and manufacture this type of medicinal product.
Inject4Pain will strengthen the collaboration between Bluepharma and the University of Coimbra, with which it has been cooperating for several years in R&DT projects, namely with the Department of Chemical Engineering, given the extensive experience of this group in the synthesis of new polymers with application in the development of new pharmaceutical forms.
With Inject4Pain, Bluepharma aims to increase differentiation and international competitiveness through the Research and Development (R&D) of new biomaterials and the subsequent application in R&D of an innovative drug in the pharmaceutical form of a complex, polymeric-based injectable, which responds to a clear market and medical need that is unmet.